Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.

LeWitt PA, Jennings D, Lyons KE, Pahwa R, Rabinowicz AL, Wang J, Guarnieri M, Hubble JP, Murck H.

Mov Disord. 2009 Jul 15;24(9):1319-24. doi: 10.1002/mds.22587.

PMID:
19412946
2.

Long-term evaluation of deep brain stimulation of the thalamus.

Pahwa R, Lyons KE, Wilkinson SB, Simpson RK Jr, Ondo WG, Tarsy D, Norregaard T, Hubble JP, Smith DA, Hauser RA, Jankovic J.

J Neurosurg. 2006 Apr;104(4):506-12.

PMID:
16619653
3.

Apolipoprotein E controls the risk and age at onset of Parkinson disease.

Li YJ, Hauser MA, Scott WK, Martin ER, Booze MW, Qin XJ, Walter JW, Nance MA, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Goetz CG, Small GW, Mastaglia F, Haines JL, Pericak-Vance MA, Vance JM.

Neurology. 2004 Jun 8;62(11):2005-9.

PMID:
15184605
4.

Vagus nerve stimulation for essential tremor: a pilot efficacy and safety trial.

Handforth A, Ondo WG, Tatter S, Mathern GW, Simpson RK Jr, Walker F, Sutton JP, Hubble JP, Jankovic J.

Neurology. 2003 Nov 25;61(10):1401-5.

PMID:
14638963
5.

Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists.

Roth T, Rye DB, Borchert LD, Bartlett C, Bliwise DL, Cantor C, Gorell JM, Hubble JP, Musch B, Olanow CW, Pollak C, Stern MB, Watts RL.

Sleep Med. 2003 Jul;4(4):275-80.

PMID:
14592299
6.

Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease.

Li YJ, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CR, Hauser MA, Scott WK, Small GW, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Goetz CG, Mastaglia F, Middleton LT, Roses AD, Saunders AM, Schmechel DE, Gullans SR, Haines JL, Gilbert JR, Vance JM, Pericak-Vance MA, Hulette C, Welsh-Bohmer KA.

Hum Mol Genet. 2003 Dec 15;12(24):3259-67. Epub 2003 Oct 21. Erratum in: Hum Mol Genet. 2004 Mar 1;13(5):573.

PMID:
14570706
7.

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

Hauser RA, Hubble JP, Truong DD; Istradefylline US-001 Study Group.

Neurology. 2003 Aug 12;61(3):297-303.

PMID:
12913187
8.

Association study of Parkin gene polymorphisms with idiopathic Parkinson disease.

Oliveira SA, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons KE, Pahwa R, Stern MB, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Scott BL, Goetz CG, Small GW, Mastaglia FL, Stajich JM, Zhang F, Booze MW, Reaves JA, Middleton LT, Haines JL, Pericak-Vance MA, Vance JM, Martin ER.

Arch Neurol. 2003 Jul;60(7):975-80.

PMID:
12873854
9.

Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.

Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Ondo WG, Allen FH Jr, Scott BL, Goetz CG, Small GW, Mastaglia F, Stajich JM, Zhang F, Booze MW, Winn MP, Middleton LT, Haines JL, Pericak-Vance MA, Vance JM.

Ann Neurol. 2003 May;53(5):624-9.

PMID:
12730996
10.

Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease.

van der Walt JM, Martin ER, Scott WK, Zhang F, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Mastaglia F, Roses AD, Stajich JM, Booze MW, Fujiwara K, Gibson RA, Middleton LT, Scott BL, Pericak-Vance MA, Vance JM.

Neurology. 2003 Apr 8;60(7):1189-91.

PMID:
12682333
11.

Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease.

van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Mastaglia F, Stajich JM, McLaurin AC, Middleton LT, Scott BL, Schmechel DE, Pericak-Vance MA, Vance JM.

Am J Hum Genet. 2003 Apr;72(4):804-11. Epub 2003 Feb 28.

12.

PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study.

DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan KM, Slater KM, Saint-Hilaire MH, Feldman RG, Suchowersky O, Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, Stacy M, MacDonald ME, Gusella JF, Myers RH.

Am J Hum Genet. 2002 May;70(5):1089-95. Epub 2002 Mar 27.

13.

Long-term studies of dopamine agonists.

Hubble JP.

Neurology. 2002 Feb 26;58(4 Suppl 1):S42-50. Review.

PMID:
11909984
14.

Age at onset in two common neurodegenerative diseases is genetically controlled.

Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Allen FA Jr, Goetz CG, Mastaglia F, Stajich JM, Gibson RA, Middleton LT, Saunders AM, Scott BL, Small GW, Nicodemus KK, Reed AD, Schmechel DE, Welsh-Bohmer KA, Conneally PM, Roses AD, Gilbert JR, Vance JM, Haines JL, Pericak-Vance MA.

Am J Hum Genet. 2002 Apr;70(4):985-93. Epub 2002 Mar 1.

15.

Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease.

Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Masterman D, Mastaglia F, Laing NG, Stajich JM, Ribble RC, Booze MW, Rogala A, Hauser MA, Zhang F, Gibson RA, Middleton LT, Roses AD, Haines JL, Scott BL, Pericak-Vance MA, Vance JM.

JAMA. 2001 Nov 14;286(18):2245-50.

16.

Complete genomic screen in Parkinson disease: evidence for multiple genes.

Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Masterman D, Mastaglia F, Laing NG, Stajich JM, Slotterbeck B, Booze MW, Ribble RC, Rampersaud E, West SG, Gibson RA, Middleton LT, Roses AD, Haines JL, Scott BL, Vance JM, Pericak-Vance MA.

JAMA. 2001 Nov 14;286(18):2239-44.

PMID:
11710888
17.

Genome-wide scan for Parkinson's disease: the GenePD Study.

DeStefano AL, Golbe LI, Mark MH, Lazzarini AM, Maher NE, Saint-Hilaire M, Feldman RG, Guttman M, Watts RL, Suchowersky O, Lafontaine AL, Labelle N, Lew MF, Waters CH, Growdon JH, Singer C, Currie LJ, Wooten GF, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Stacy M, Montgomery E, MacDonald ME, Gusella JF, Myers RH.

Neurology. 2001 Sep 25;57(6):1124-6.

PMID:
11571351
18.

Pramipexole: a nonergot dopamine agonist as drug therapy in Parkinson's disease.

Hubble JP, Novak P.

Expert Rev Neurother. 2001 Sep;1(1):43-51. doi: 10.1586/14737175.1.1.43.

PMID:
19811045
19.

Pre-clinical studies of pramipexole: clinical relevance.

Hubble JP.

Eur J Neurol. 2000 May;7 Suppl 1:15-20. Review.

PMID:
11054154
20.

Test-retest reliability of an epidemiological instrument for Parkinson's disease.

Reider CR, Hubble JP.

J Clin Epidemiol. 2000 Aug;53(8):863-5.

PMID:
10942870
21.

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.

Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW.

Mov Disord. 2000 May;15(3):485-9.

PMID:
10830413
22.

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease.

Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW.

Mov Disord. 2000 May;15(3):485-489. doi: 10.1002/1531-8257(200005)15:3<485::AID-MDS1010>3.0.CO;2-F.

PMID:
28470730
23.

Novel drugs for Parkinson's disease.

Hubble JP.

Med Clin North Am. 1999 Mar;83(2):525-36. Review.

PMID:
10093592
24.

Aging and the basal ganglia.

Hubble JP.

Neurol Clin. 1998 Aug;16(3):649-57. Review.

PMID:
9666042
25.

Double-blind controlled trial of gabapentin in essential tremor.

Pahwa R, Lyons K, Hubble JP, Busenbark K, Rienerth JD, Pahwa A, Koller WC.

Mov Disord. 1998 May;13(3):465-7.

PMID:
9613738
26.

Gene-toxin interaction as a putative risk factor for Parkinson's disease with dementia.

Hubble JP, Kurth JH, Glatt SL, Kurth MC, Schellenberg GD, Hassanein RE, Lieberman A, Koller WC.

Neuroepidemiology. 1998;17(2):96-104.

PMID:
9592786
27.

Gender differences in Parkinson's disease.

Lyons KE, Hubble JP, Tröster AI, Pahwa R, Koller WC.

Clin Neuropharmacol. 1998 Mar-Apr;21(2):118-21.

PMID:
9579298
28.

Clinical expression of essential tremor: effects of gender and age.

Hubble JP, Busenbark KL, Pahwa R, Lyons K, Koller WC.

Mov Disord. 1997 Nov;12(6):969-72.

PMID:
9399222
29.

Effects of thalamic deep brain stimulation based on tremor type and diagnosis.

Hubble JP, Busenbark KL, Wilkinson S, Pahwa R, Paulson GW, Lyons K, Koller WC.

Mov Disord. 1997 May;12(3):337-41.

PMID:
9159728
30.

Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy.

Anouti A, Schmidt K, Lyons KE, Hubble JP, Schellenberg G, Golbe LI, Lang AE, Galvez-Jimenez N, Hershey L, Koller WC.

Neurology. 1996 Apr;46(4):1156-7.

PMID:
8780111
31.

Deep brain stimulation for essential tremor.

Hubble JP, Busenbark KL, Wilkinson S, Penn RD, Lyons K, Koller WC.

Neurology. 1996 Apr;46(4):1150-3.

PMID:
8780109
32.

Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa.

Pahwa R, Lyons K, McGuire D, Dubinsky R, Hubble JP, Koller WC.

Neurology. 1996 Apr;46(4):1059-62.

PMID:
8780091
33.

Risk factors for dementia in Parkinson's disease: effect of education.

Glatt SL, Hubble JP, Lyons K, Paolo A, Tröster AI, Hassanein RE, Koller WC.

Neuroepidemiology. 1996 Jan-Feb;15(1):20-5.

PMID:
8719045
34.

Nocardia species as an etiologic agent in Parkinson's disease: serological testing in a case-control study.

Hubble JP, Cao T, Kjelstrom JA, Koller WC, Beaman BL.

J Clin Microbiol. 1995 Oct;33(10):2768-9.

35.

Erythrocyte thiolmethyltransferase: another failed marker for Alzheimer's and Parkinson's diseases.

Hurwitz A, Hubble JP, Glatt SL, Koller WC, Pollack J.

Neurology. 1995 Oct;45(10):1903-6.

PMID:
7477990
36.

Pramipexole in patients with early Parkinson's disease.

Hubble JP, Koller WC, Cutler NR, Sramek JJ, Friedman J, Goetz C, Ranhosky A, Korts D, Elvin A.

Clin Neuropharmacol. 1995 Aug;18(4):338-47.

PMID:
8665547
37.

Differentiation of the dementias of Alzheimer's and Parkinson's disease with the dementia rating scale.

Paolo AM, Tröster AI, Glatt SL, Hubble JP, Koller WC.

J Geriatr Psychiatry Neurol. 1995 Jul;8(3):184-8.

PMID:
7576044
38.

Botulinum toxin treatment of essential head tremor.

Pahwa R, Busenbark K, Swanson-Hyland EF, Dubinsky RM, Hubble JP, Gray C, Koller WC.

Neurology. 1995 Apr;45(4):822-4.

PMID:
7723978
39.

The influence of depression on cognition in Parkinson's disease: a pattern of impairment distinguishable from Alzheimer's disease.

Tröster AI, Paolo AM, Lyons KE, Glatt SL, Hubble JP, Koller WC.

Neurology. 1995 Apr;45(4):672-6.

PMID:
7723954
40.

Apolipoprotein E genotypes in Parkinson's disease with and without dementia.

Koller WC, Glatt SL, Hubble JP, Paolo A, Tröster AI, Handler MS, Horvat RT, Martin C, Schmidt K, Karst A, et al.

Ann Neurol. 1995 Feb;37(2):242-5.

PMID:
7847865
41.

The parkinsonian personality.

Hubble JP, Koller WC.

Adv Neurol. 1995;65:43-8. Review. No abstract available.

PMID:
7872151
42.

Influence of demographic variables on the Dementia Rating Scale.

Paolo AM, Tröster AI, Glatt SL, Hubble JP, Koller WC.

J Geriatr Psychiatry Neurol. 1995 Jan;8(1):38-41.

PMID:
7710645
43.

Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists.

Hadjiconstantinou M, Hubble JP, Wemlinger TA, Neff NH.

J Pharmacol Exp Ther. 1994 Aug;270(2):639-44.

PMID:
7915317
44.

Personality and depression in Parkinson's disease.

Hubble JP, Venkatesh R, Hassanein RE, Gray C, Koller WC.

J Nerv Ment Dis. 1993 Nov;181(11):657-62.

PMID:
8228945
45.

Risk factors for Parkinson's disease.

Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC.

Neurology. 1993 Sep;43(9):1693-7.

PMID:
8414014
46.

Interactive video conferencing: a means of providing interim care to Parkinson's disease patients.

Hubble JP, Pahwa R, Michalek DK, Thomas C, Koller WC.

Mov Disord. 1993 Jul;8(3):380-2.

PMID:
8341308
47.

Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors.

Hadjiconstantinou M, Wemlinger TA, Sylvia CP, Hubble JP, Neff NH.

J Neurochem. 1993 Jun;60(6):2175-80.

PMID:
8492125
48.

Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease.

Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC.

Neurology. 1993 Apr;43(4):677-81.

PMID:
8469321
49.

Effects of selegiline dosing on motor fluctuations in Parkinson's disease.

Hubble JP, Koller WC, Waters C.

Clin Neuropharmacol. 1993 Feb;16(1):83-7.

PMID:
8422661
50.

Interactive video conferencing and Parkinson's disease.

Hubble JP.

Kans Med. 1992 Dec;93(12):351-2. No abstract available.

PMID:
1287283

Supplemental Content

Loading ...
Support Center